Does MTHFD1 rs2236225 reduce folate-cycle throughput and increase homocysteine risk under high methylation demand?

The MTHFD1 rs2236225 (G1958A, R653Q) polymorphism is a well-characterized genetic variant that directly compromises cytosolic one-carbon flow, altering metabolic resilience under physiological methylation demands.

Mechanistic impact on the folate cycle

• Enzymatic destabilization: The rs2236225 variant acts as a hypomorphic allele that destabilizes the C-terminal 10-formyltetrahydrofolate synthetase domain of the trifunctional cytosolic MTHFD1 enzyme.
• Reduced pathway flux: This structural instability accelerates protein degradation, resulting in an approximate 25% reduction in overall cytosolic MTHFD1 metabolic activity. This bottleneck limits the conversion of mitochondrially derived formate into the cytosolic 10-formyl-THF pool required for de novo purine and nucleotide synthesis.

Homocysteine accumulation and nutrient stress

• Homocysteine regulation: Because MTHFD1 operates upstream of the MTHFR-MTR pathway, restricted throughput directly compromises homocysteine remethylation. Controlled human trials show that individuals with the MTHFD1 1958AA genotype display higher homocysteine levels during dietary folate restriction, which resolve upon folate repletion.
• Sensitivities to choline deficiency: When folate-cycle throughput is constrained, the body relies more heavily on the backup betaine-homocysteine methyltransferase pathway. Under choline restriction, carriers of the 1958A allele exhibit heightened sensitivity, which manifests as elevated plasma homocysteine, muscle damage, and fatty liver.

Bottom line

• The MTHFD1 rs2236225 variant causes a ~25% reduction in enzyme activity that limits folate-cycle throughput. This genetic constraint increases susceptibility to elevated homocysteine and tissue damage under conditions of high methylation demand or dietary folate and choline deficiency.